Study of andecaliximab for preventing bone growth after spinal cord injury
Part of Bones, joints & muscles, Injuries & trauma clinical trials.
This trial tests a drug called andecaliximab to see if it can stop abnormal bone growth (heterotopic ossification) that sometimes happens after a spinal cord injury. It is for people who are at high risk for this bone growth and aims to prevent it from forming.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 89 years old.
- You had a traumatic spinal cord injury at least 10 days ago.
- You are at risk for abnormal bone growth, which will be checked with scans.
- You can give informed consent or have a legal representative do so.
- You agree to follow the study schedule and procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called CE-1 for people with spinal cord injuries caused by trauma. The treatment is given as an injection into the fluid around the spinal cord, to see if it helps improve neurological function.
This trial tests a new treatment for early-stage hip bone death (avascular necrosis) where a substance called exosomes from stem cells is injected directly into the hip joint to see if it is safe and may help repair the bone.
This Phase 2 trial tests sotateltide (PMZ-1620) in people with a recent spinal cord injury. It aims to see whether the drug can improve neurological recovery after injury, especially in certain levels and types of incomplete injuries.
This Phase 1 study tests whether an off-the-shelf stem cell product made from donated umbilical cord tissue is safe for people with spinal cord injury. It mainly looks at side effects and safety, and may help pave the way for future effectiveness studies.
This trial tests a device that delivers a special cell therapy (LCTOPC1) into the spinal cord. It is for people with a recent or chronic spinal cord injury that is severe (no feeling or movement below the injury) or leaves some sensation but no movement.
This trial tests a new drug called AGA2115 for people with osteogenesis imperfecta (also known as brittle bone disease) who have a confirmed genetic change in the COL1A1 or COL1A2 genes. The study aims to see if the drug can help strengthen bones and reduce fracture risk.
Hear when a new Heterotopic Ossification (HO) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.